Page last updated: 2024-11-06

isopropalin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Isopropalin is a pre-emergent herbicide used to control broadleaf weeds in various crops, such as soybeans, peanuts, and cotton. Its synthesis involves a multi-step process that begins with the reaction of 2,6-dichloroaniline with 2-methyl-1-propanol. This reaction forms a key intermediate, which is then reacted with isobutylene oxide to yield isopropalin. Isopropalin inhibits the growth of weeds by disrupting the formation of microtubules, which are essential for cell division and growth. It has been found to be effective in controlling a wide range of weed species, including pigweed, ragweed, and crabgrass. Its use in agriculture has been crucial for maintaining crop yields and minimizing weed competition. Due to its effectiveness and environmental impact, isopropalin has been extensively studied to understand its fate and transport in the environment. Researchers investigate its degradation pathways, potential leaching into groundwater, and its effects on non-target organisms. '

isopropalin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID36606
CHEMBL ID1256728
CHEBI ID82189
SCHEMBL ID55296
MeSH IDM0051842

Synonyms (48)

Synonym
4-isopropyl-2,6-dinitro-n,n-dipropylaniline
brn 2762577
paarlan
epa pesticide chemical code 100201
isopropaline [iso-french]
hsdb 6687
cumidine, 2,6-dinitro-n,n-dipropyl-
2,6-dinitro-n,n-dipropylcumidine
caswell no. 506a
el-179
aniline, 2,6-dinitro-n,n-dipropyl-p-isopropyl-
isopropaline
2,6-dinitro-n,n-dipropyl-4-isopropylaniline
4-(1-methylethyl)-2,6-dinitro-n,n-dipropylbenzenamine
isopropalin [ansi:bsi:iso]
einecs 251-690-7
benzenamine, 4-(1-methylethyl)-2,6-dinitro-n,n-dipropyl-
isopropalin
33820-53-0
(4-isopropyl-2,6-dinitrophenyl)dipropylamine
4-isopropyl-2,6-dinitro-n,n-dipropyl-aniline
2,6-dinitro-4-propan-2-yl-n,n-dipropylaniline
NCGC00248025-02
NCGC00248025-01
C19063
CHEMBL1256728
chebi:82189 ,
NCGC00259777-01
cas-33820-53-0
tox21_300422
dtxsid8024157 ,
tox21_202228
NCGC00254366-01
dtxcid904157
unii-52gzd1i41n
52gzd1i41n ,
AKOS015892015
SCHEMBL55296
isopropalin [mi]
isopropalin [hsdb]
isopropalin [iso]
NEKOXWSIMFDGMA-UHFFFAOYSA-N
n-(4-isopropyl-2,6-dinitrophenyl)-n,n-dipropylamine #
el 179
isopropalin, pestanal(r), analytical standard
isopropalin, analytical standard
J-019332
Q27155794

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency2.73060.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency39.36140.000221.22318,912.5098AID1259243; AID743035; AID743042; AID743063
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency16.82220.001022.650876.6163AID1224838; AID1224839
progesterone receptorHomo sapiens (human)Potency33.64340.000417.946075.1148AID1346795
retinoid X nuclear receptor alphaHomo sapiens (human)Potency19.09140.000817.505159.3239AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency67.12740.001530.607315,848.9004AID1224841
pregnane X nuclear receptorHomo sapiens (human)Potency21.57440.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency23.86600.000229.305416,493.5996AID743069; AID743075
thyroid stimulating hormone receptorHomo sapiens (human)Potency7.77520.001628.015177.1139AID1224843; AID1224895
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency64.12900.000323.4451159.6830AID743065; AID743067
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID522809Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin H28Q mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522806Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin V4L mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522816Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243S mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522812Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235T mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522810Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin L136F mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522808Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin F24H mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522805Antimicrobial activity against Toxoplasma gondii RH infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522807Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin S6I mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522813Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235V mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522811Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235L mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522815Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243C mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
AID522814Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin T239I mutation infected in HFF cells by plaque assay2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Dinitroaniline activity in Toxoplasma gondii expressing wild-type or mutant alpha-tubulin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (33.33)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's1 (16.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.49 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index29.80 (26.88)
Search Engine Supply Index2.60 (0.95)

This Compound (26.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]